|
|
Article: Maxygen and Rentschler Sign Agreement to Manufacture Novel G-CSF.
- Article from:
- PR Newswire
- Article date:
- September 9, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Maxygen, Inc. and Rentschler Biotechnologie GmbH today announced the signing of an agreement for the scale-up and manufacture of Phase I and Phase II clinical supplies of Maxygen's next-generation granulocyte cell stimulating factor (G-CSF) molecule.
Maxygen has developed a next-generation G-CSF that preclinical studies suggest reduces the duration of neutropenia in comparison to currently marketed products while maintaining the convenience of once-weekly dosing. Preclinical data obtained in established neutropenia models in primate, rat, and mouse suggest that Maxygen's product candidate reduces the duration of neutropenia by clinically relevant shorter periods ...